These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1281 related articles for article (PubMed ID: 26996339)

  • 1. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
    Rofagha S; Bhisitkul RB; Boyer DS; Sadda SR; Zhang K;
    Ophthalmology; 2013 Nov; 120(11):2292-9. PubMed ID: 23642856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study.
    Bhisitkul RB; Mendes TS; Rofagha S; Enanoria W; Boyer DS; Sadda SR; Zhang K
    Am J Ophthalmol; 2015 May; 159(5):915-24.e2. PubMed ID: 25640411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
    Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J
    Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
    Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
    Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.
    Weinberg DV; Shapiro H; Ehrlich JS
    Ophthalmology; 2013 Jun; 120(6):1278-82. PubMed ID: 23453513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
    Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
    Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
    Bailey C; Scott LJ; Rogers CA; Reeves BC; Hamill B; Peto T; Chakravarthy U; Harding SP;
    Ophthalmology; 2019 Jan; 126(1):75-86. PubMed ID: 30301555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
    Inan S; Baysal Z; Inan UU
    Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
    Zweifel SA; Saroj N; Shapiro H; Freund KB
    Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
    ; Maguire MG; Martin DF; Ying GS; Jaffe GJ; Daniel E; Grunwald JE; Toth CA; Ferris FL; Fine SL
    Ophthalmology; 2016 Aug; 123(8):1751-1761. PubMed ID: 27156698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Macular Atrophy Detected by Fundus Autofluorescence in Patients With Neovascular Age-Related Macular Degeneration After Long-Term Ranibizumab Treatment.
    Kuehlewein L; Dustin L; Sagong M; Hariri A; Mendes TS; Rofagha S; Bhisitkul RB; Sadda SR
    Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):224-31. PubMed ID: 26985795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials.
    Rosenfeld PJ; Shapiro H; Ehrlich JS; Wong P;
    Am J Ophthalmol; 2011 Nov; 152(5):793-8. PubMed ID: 21794843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.
    Barbazetto IA; Saroj N; Shapiro H; Wong P; Ho AC; Freund KB
    Am J Ophthalmol; 2010 Jun; 149(6):939-946.e1. PubMed ID: 20378094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
    Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
    Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in Fellow Eyes of Previously Treated Patients With Neovascular Age-Related Macular Degeneration.
    Stem MS; Moinuddin O; Kline N; Thanos A; Rao P; Williams GA; Hassan TS
    JAMA Ophthalmol; 2018 Jul; 136(7):820-823. PubMed ID: 29800991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.